<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 5)
BioSource International, Inc.
__________________
(Name of Issuer)
Common Stock, par value $0.001 per share
___________________________
(Title of Class of Securities)
09066H104
---------
(CUSIP Number)
Genstar Capital LLC
555 California Street, Suite 4850
San Francisco, California 94104
(415) 834-2350
______________________________________________
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copy to:
Scott R. Haber
Latham & Watkins
505 Montgomery Street, Suite 1900
San Francisco, California 94111-2562
(415) 391-0600
October 25, 2000
__________________________________________________
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [ ].
(Continued on following pages)
<PAGE>
SCHEDULE 13D
--------------------------------- --------------------------
CUSIP NO. 09066H104 Page 2 of 14 Pages
--------------------------------- --------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Genstar Capital LLC
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
AF,OO
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Delaware
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-3,200,553- shares of Common Stock (includes 1,262,542
Owned By shares of Common Stock issuable upon exercise of
Warrants)
-----------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
10. Shared Dispositive Power
With
-3,200,553- shares of Common Stock (includes 1,262,542
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,200,553- shares of Common Stock (includes 1,262,542 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
31.9%
------------------------------------------------------------------------------
14. Type of Reporting Person
OO
------------------------------------------------------------------------------
2
<PAGE>
SCHEDULE 13D
--------------------------------- --------------------------
CUSIP NO. 09066H104 Page 3 of 14 Pages
--------------------------------- --------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Genstar Capital Partners II, L.P.
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
AF,OO
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Delaware
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-3,200,553- shares of Common Stock (includes 1,262,542
Owned By shares of Common Stock issuable upon exercise of
Warrants)
-----------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
10. Shared Dispositive Power
With
-3,200,553- shares of Common Stock (includes 1,262,542
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,200,553- shares of Common Stock (includes 1,262,542 shares of Common
Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
31.9%
------------------------------------------------------------------------------
14. Type of Reporting Person
PN
------------------------------------------------------------------------------
3
<PAGE>
SCHEDULE 13D
--------------------------------- ----------------------------
CUSIP NO. 09066H104 Page 4 of 14 Pages
--------------------------------- ----------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Stargen II LLC
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
AF,OO
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Delaware
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-0- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-57,480- shares of Common Stock (includes 24,458
Owned By shares of Common Stock issuable upon exercise of
Warrants)
-----------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting -0- shares of Common Stock
Person -----------------------------------------------------------
10. shared dispositive power
With
-57,480- shares of Common Stock (includes 24,458
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-57,480- shares of Common Stock (includes 24,458 shares of Common Stock
issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
0.7%
------------------------------------------------------------------------------
14. Type of Reporting Person
OO
------------------------------------------------------------------------------
<PAGE>
SCHEDULE 13D
--------------------------------- ----------------------------
CUSIP NO. 09066H104 Page 5 of 14 Pages
--------------------------------- ----------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Jean-Pierre L. Conte
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
United States of America
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-15,000- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-3,273,033- shares of Common Stock (includes
Owned By 1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
Each
-----------------------------------------------------------
Reporting 9. Sole Dispositive Power
Person -15,000- shares of Common Stock
With -----------------------------------------------------------
10. Shared Dispositive Power
-3,273,033- shares of Common Stock (includes
1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,288,033- shares of Common Stock (includes 1,287,000 shares of
Common Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
32.7%
------------------------------------------------------------------------------
14. Type of Reporting Person
IN
------------------------------------------------------------------------------
5
<PAGE>
SCHEDULE 13D
--------------------------------- ----------------------------
CUSIP NO. 09066H104 Page 6 of 14 Pages
--------------------------------- ----------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Richard F. Hoskins
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
United States of America
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-16,667- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-3,258,033- shares of Common Stock (includes
Owned By 1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting -16,667- shares of Common Stock
Person -----------------------------------------------------------
10. Shared Dispositive Power
With
-3,258,033- shares of Common Stock (includes 1,287,000
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,274,700- shares of Common Stock (includes 1,287,000 shares
of Common Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
32.6%
------------------------------------------------------------------------------
14. Type of Reporting Person
IN
------------------------------------------------------------------------------
6
<PAGE>
SCHEDULE 13D
--------------------------------- ----------------------------
CUSIP NO. 09066H104 Page 7 of 14 Pages
--------------------------------- ----------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Richard D. Paterson
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Canada
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-16,667- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-3,258,033- shares of Common Stock (includes
Owned By 1,287,000 shares of Common Stock issuable upon
exercise of Warrants)
-----------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting -16,667- shares of Common Stock
Person -----------------------------------------------------------
10. Shared Dispositive Power
With
-3,258,033- shares of Common Stock (includes 1,287,000
shares of Common Stock issuable upon exercise of
Warrants)
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,274,700- shares of Common Stock (includes 1,287,000 shares
of Common Stock issuable upon exercise of Warrants)
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
32.6%
------------------------------------------------------------------------------
14. Type of Reporting Person
IN
------------------------------------------------------------------------------
7
<PAGE>
SCHEDULE 13D
--------------------------------- ----------------------------
CUSIP NO. 09066H104 Page 8 of 14 Pages
--------------------------------- ----------------------------
------------------------------------------------------------------------------
1. Name of Reporting Person
Robert J. Weltman
------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [_]
(b) [X]
------------------------------------------------------------------------------
3. SEC Use Only
------------------------------------------------------------------------------
4. Source of Funds
PF, AF
------------------------------------------------------------------------------
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items 2(d) or 2(e) [_]
------------------------------------------------------------------------------
6. Citizenship or Place of Organization
United States of America
------------------------------------------------------------------------------
7. Sole Voting Power
Number of
-3,333- shares of Common Stock
Shares -----------------------------------------------------------
8. Shared Voting Power
Beneficially
-0- shares of Common Stock
Owned By
-----------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting -3,333- shares of Common Stock
Person -----------------------------------------------------------
10. Shared Dispositive Power
With
-0- shares of Common Stock
------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
-3,333- shares of Common Stock
------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
[_]
------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
0.0%
------------------------------------------------------------------------------
14. Type of Reporting Person
IN
------------------------------------------------------------------------------
8
<PAGE>
This Amendment No. 5 to Schedule 13D ("Amendment No. 5") amends the
Schedule 13D filed with the Securities and Exchange Commission (the
"Commission") on January 20, 2000, as amended (collectively, the "Schedule 13D")
by Genstar Capital LLC, a Delaware limited liability company ("Genstar
Capital"), Genstar Capital Partners II, L.P., a Delaware limited partnership
("Genstar Capital Partners"), Stargen II LLC, a Delaware limited liability
company ("Stargen"), Jean-Pierre L. Conte, an individual ("Mr. Conte"), Richard
F. Hoskins, an individual ("Mr. Hoskins"), Richard D. Paterson, an individual
("Mr. Paterson") and Robert J. Weltman, an individual ("Mr. Weltman" and,
together with Genstar Capital, Genstar Capital Partners, Stargen, Mr. Conte, Mr.
Hoskins and Mr. Paterson, the "Reporting Persons"), relating to shares of common
stock, par value $0.001 per share (the "Common Stock"), of BioSource
International, Inc., a Delaware corporation ("BioSource" or the "Company").
Unless otherwise indicated, all capitalized terms used herein but not defined
herein shall have the same meanings as set forth in the Schedule 13D.
Item 3. Source and Amount of Funds.
--------------------------
Item 3 to the Schedule 13D is hereby amended to add the following
information:
Genstar Capital Partners, Messrs. Conte, Hoskins, Paterson and Weltman
purchased 233,333, 30,000, 16,667, 16,667 and 3,333 of the Shares, respectively,
at $15 per share or aggregate purchase prices of $3,499,995, $450,000, $250,005,
$250,005 and $49,995, respectively. The funds used by Genstar Capital Partners
were obtained from capital contributions of its partners. The funds used by
Messrs. Conte, Hoskins, Paterson and Weltman were obtained from their respective
personal funds. The funds were delivered to the Company on September 29, 2000.
The purchase was completed on October 25, 2000 upon receipt of certain
regulatory approvals.
Item 4. Purpose of the Transaction.
--------------------------
Item 4 to the Schedule 13D is hereby amended to add the following
information:
Pursuant to the Amendment to Securities Purchase Agreement dated
September 28, 2000 (the "Amendment") by and among BioSource, Genstar Capital
Partners, Mr. Conte, Mr. Hoskins, Mr. Paterson and Mr. Weltman, (i) Genstar
Capital Partners purchased 233,333 of the Shares, (ii) Mr. Conte purchased
30,000 of the Shares, (iii) Mr. Hoskins purchased 16,667 of the Shares, (iv) Mr.
Paterson purchased 16,667 of the Shares and (v) Mr. Weltman purchased 3,333 of
the Shares. The funds for the purchase were delivered to BioSource on September
29, 2000, with the purchase occurring on October 25, 2000. A copy of the
Amendment is attached hereto as Exhibit 4 and is incorporated by reference
herein. A copy of the Second Amendment to the Investor Rights Agreement, which
provides that upon closing of the purchases of Shares, Messrs. Conte, Hoskins,
Paterson and Weltman shall be parties to the Investor Rights Agreement and that
the Shares purchased by each of them shall constitute "Registrable Securities"
under the Investor Rights Agreement, is attached hereto as Exhibit 5 and is
incorporated by reference herein.
9
<PAGE>
Item 5. Interest in Securities of the Issuer.
------------------------------------
Item 5 to the Schedule 13D is hereby amended to add the following
information:
(a) and (b). As a result of the purchase of the shares of Common
Stock described below under Item 5(c), Genstar Capital Partners beneficially
owns 3,200,553 shares of Common Stock, which represents 31.9% of the Common
Stock outstanding (assuming exercise of the Warrants held by Genstar Capital
Partners). As a result of the purchase of the shares of Common Stock described
below under Item 5(c), Stargen beneficially owns 57,480 shares of Common Stock,
which represents 0.7% of the Common Stock outstanding (assuming exercise of the
Warrants held by Stargen). In addition to the Shares beneficially owned by
Genstar Capital Partners and Stargen, Mr. Conte holds 30,000 shares of Common
Stock in revocable trusts for the benefit of Mr. Conte and his wife, which
represents less than 0.1% of the Common Stock outstanding, Mr. Hoskins holds
16,667 shares of Common Stock in a revocable trust for the benefit of Mr.
Hoskins and his family, which represents less than 0.1% of the Common Stock
outstanding, Mr. Paterson holds 16,667 shares of Common Stock in a revocable
trust for the benefit of Mr. Paterson and his family, which represents less than
0.1% of the Common Stock outstanding, and Mr. Weltman beneficially owns 3,333
shares of Common Stock directly, which represents less than 0.1% of the Common
Stock outstanding. As a result of the purchase of the shares of Common Stock
described below under Item 5(c), the Reporting Persons beneficially own
3,324,700 shares of Common Stock, which represents 33.1% of the Common Stock
outstanding (assuming exercise of the Warrants held by Genstar Capital Partners
and Stargen).
Genstar Capital Partners has the sole power to dispose or direct the
disposition of the Warrants and shares of Common Stock which it holds directly
or the shares of Common Stock issued upon exercise of such Warrants. Genstar
Capital Partners does not have the power to vote or direct the vote of any of
the shares of Common Stock which it would own upon exercise of such Warrants
prior to the receipt of such shares of Common Stock upon exercise of such
Warrants. Genstar Capital Partners has the power to vote or direct the vote of
the shares of Common Stock which it holds directly.
Genstar Capital is the sole general partner of Genstar Capital Partners
and in such capacity may be deemed to have the power to dispose or direct the
disposition of the Warrants and shares of Common Stock held by Genstar Capital
Partners, and shares of Common Stock which Genstar Capital Partners would hold
upon exercise of such Warrants, and to vote or direct the vote of such shares of
Common Stock.
Stargen has the sole power to dispose or direct the disposition of the
Warrants and shares of Common Stock which it holds directly and the shares of
Common Stock issued upon exercise of such Warrants. Stargen does not have the
power to vote or direct the vote of any of the shares of Common Stock which it
would own upon exercise of such Warrants prior to the receipt of such shares of
Common Stock upon exercise of such Warrants. Stargen has the power to vote or
direct the vote of the shares of Common Stock which it holds directly.
Messrs. Conte, Hoskins and Paterson are the managers and managing
directors of Genstar Capital and are members of Stargen, and Mr. Paterson is the
Administrative Member of Stargen, and in such capacity may be deemed to have the
power to dispose or direct the disposition of the
10
<PAGE>
Warrants and shares of Common Stock held by the Investors, and shares of Common
Stock which the Investors would own upon exercise of such Warrants, and may be
deemed to have the power to vote or direct the vote of such shares of Common
Stock. Mr. Weltman is a Vice President and a member (but not a managing member)
of Genstar Capital and a member (but not a managing member) of Stargen. Mr.
Weltman does not have power to vote or dispose of, or to direct the voting or
disposition of, any securities beneficially owned by Genstar Capital or Stargen.
Mr. Weltman disclaims that he beneficially owns any shares of Common Stock
beneficially owned by Genstar Capital Partners or Stargen, except to the extent
of his economic interest therein.
Mr. Conte has the sole power to dispose or direct the disposition of,
and to vote or direct the vote of, 15,000 of the shares of Common Stock that he
holds in trust for the benefit of himself and his wife, and shared power with
his wife to dispose or direct the disposition of, and to vote or direct the vote
of, the remaining 15,000 of the shares of Common Stock that he holds in trust
for the benefit of himself and his wife. Each of Messrs. Hoskins and Paterson
has the sole power to dispose or direct the disposition of, and to vote or
direct he vote of, the shares of Common Stock that each of them holds in trust
for the benefit of himself and his family. Mr. Weltman has the sole power to
dispose or direct the disposition of, and to vote or direct the vote of, the
shares of Common Stock that he holds directly.
The Reporting Persons may be deemed to be acting as a group in relation
to their respective holdings in BioSource, but do not affirm the existence of
any such group.
Except as set forth in this Item 5(a)-(b), each of the persons named in
this Item 5(a)-(b) disclaims beneficial ownership of any Common Stock owned
beneficially or of record by any other person named in this Item 5(a)-(b).
(c) Pursuant to the Amendment (i) Genstar Capital Partners purchased
233,333 of the Shares, (ii) Mr. Conte purchased 30,000 of the Shares, (iii) Mr.
Hoskins purchased 16,667 of the Shares, (iv) Mr. Paterson purchased 16,667 of
the Shares and (v) Mr. Weltman purchased 3,333 of the Shares. The funds for the
purchase were delivered to BioSource on September 29, 2000, with the purchase
occurring on October 25, 2000. A copy of the Amendment is attached hereto as
Exhibit 4 and is incorporated by reference herein.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to
------------------------------------------------------------------------
Securities of the Issuer.
------------------------
Item 6 to the Schedule 13D is hereby amended to add the following
information:
Pursuant to the Amendment (i) Genstar Capital Partners purchased 233,333
of the Shares, (ii) Mr. Conte purchased 30,000 of the Shares, (iii) Mr. Hoskins
purchased 16,667 of the Shares, (iv) Mr. Paterson purchased 16,667 of the Shares
and (v) Mr. Weltman purchased 3,333 of the Shares. The funds for the purchase
were delivered to BioSource on September 29, 2000, with the purchase occurring
on October 25, 2000. A copy of the Amendment is attached hereto as Exhibit 4 and
is incorporated by reference herein. A copy of the Second Amendment to the
Investor Rights Agreement, which provides that upon closing of the purchases of
Shares, Messrs. Conte, Hoskins, Paterson and Weltman shall be parties to the
Investor Rights Agreement and that the Shares purchased by each of them shall
constitute "Registrable Securities" under the Investor Rights Agreement, is
attached hereto as Exhibit 5 and is incorporated by reference herein.
11
<PAGE>
Item 7. Material to be Filed as Exhibits.
--------------------------------
Exhibit 1 Joint Filing Agreement (incorporated by reference
to the Schedule 13D).
Exhibit 2 Power of Attorney for Robert J. Weltman
(incorporated by reference to the Schedule 13D).
Exhibit 3 Power of Attorney for each of Messrs. Hoskins and
Paterson.
Exhibit 4 Amendment to Securities Purchase Agreement by and
among BioSource, Genstar Capital Partners and
Messrs. Conte, Hoskins, Paterson and Weltman dated
as of September 28, 2000.
Exhibit 5 Second Amendment, dated as of September 28, 2000,
by and among BioSource, Genstar Capital Partners,
Stargen, Messrs. Conte, Hoskins, Paterson and
Weltman, Russell D. Hays and George Uveges, to the
Investor Rights Agreement, dated as of February 15,
2000, by and among BioSource, Genstar Capital
Partners and Stargen.
12
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of each of the undersigned's
knowledge and belief, each of the undersigned certifies that the information set
forth in this statement is true, complete and correct.
Dated: October 25, 2000
GENSTAR CAPITAL LLC
By: /s/ Jean-Pierre L. Conte
------------------------------------------
Name: Jean-Pierre L. Conte
Its: Managing Member
GENSTAR CAPITAL PARTNERS II, L.P.
By: Genstar Capital LLC, its general partner
By: /s/ Jean-Pierre L. Conte
------------------------------------------
Name: Jean-Pierre L. Conte
Its: Managing Member
STARGEN II LLC
By: /s/ Jean-Pierre L. Conte
------------------------------------------
Name: Jean-Pierre L. Conte
Its: Member
/s/ Jean-Pierre L. Conte
----------------------------------------------
Jean-Pierre L. Conte
/s/ Jean-Pierre L. Conte
----------------------------------------------
Jean-Pierre L. Conte
Attorney-in-fact for
Richard F. Hoskins
/s/ Jean-Pierre L. Conte
----------------------------------------------
Jean-Pierre L. Conte
Attorney-in-fact for
Richard D. Paterson
/s/ Jean-Pierre L. Conte
----------------------------------------------
Jean-Pierre L. Conte
Attorney-in-fact for
Robert J. Weltman
13
<PAGE>
EXHIBIT INDEX
-------------
Exhibit 1 Joint Filing Agreement (incorporated by reference to the
Schedule 13D).
Exhibit 2 Power of Attorney for Robert J. Weltman (incorporated by
reference to the Schedule 13D).
Exhibit 3 Power of Attorney for each of Messrs. Hoskins and Paterson.
Exhibit 4 Amendment to Securities Purchase Agreement by and among
BioSource, Genstar Capital Partners and Messrs. Conte,
Hoskins, Paterson and Weltman dated as of September 28,
2000.
Exhibit 5 Second Amendment, dated as of September 28, 2000, by and
among BioSource, Genstar Capital Partners, Stargen, Messrs.
Conte, Hoskins, Paterson and Weltman, Russell D. Hays and
George Uveges, to the Investor Rights Agreement, dated as
of February 15, 2000, by and among BioSource, Genstar
Capital Partners and Stargen.
14
